Guy Neff

机构：Florida Digestive Health Specialists, Florida Cancer Specialists & Research Institute

发表论文 244 篇 · 总被引 12060 次 · h-index 48

代表论文

• Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (2025 · New England Journal of Medicine · 被引 111)
• Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2025 · The Lancet · 被引 57)
• Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study (2025 · The Lancet · 被引 28)
• HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study (2025 · Clinical and Molecular Hepatology · 被引 11)
• Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditions (2025 · Diabetes Obesity and Metabolism · 被引 6)
• Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (2026 · Nature Medicine · 被引 3)